A Norway spruce compound whose case rests on gut bacteria converting it into a weak estrogen-like substance — the one step shown directly in people. Fewer hot flashes came from a single small study without a comparison group. Longevity and disease links come from diet and blood-marker studies. Population data point the opposite way for women with breast cancer before menopause. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum enterolactone | No established target; a rise from the individual's own baseline, typically 2–3-fold by week 8 | Confirms colonic bacteria are converting the dose; a flat result means no exposure |
| hs-CRP | Below 1.0 mg/L | Tracks the low-grade inflammation the compound's cell-culture mechanism targets |
| LDL-C | 70–100 mg/dL (1.8–2.6 mmol/L) | Rodent dosing lowered cholesterol; establishes whether any lipid movement occurs in people |
| Triglycerides | Below 90 mg/dL (1.0 mmol/L) | The clearest lipid change seen in rodent dosing, and the most diet-sensitive lipid |
| HbA1c | 5.0–5.4% | Puts the observational diabetes-incidence signal to an individual test |
| ALT | 10–26 U/L (women), 10–30 U/L (men) | Routine safety check, since long-term human exposure data do not exist |
| PSA (men over 45) | Below 1.0 ng/mL under 60; below 1.5 ng/mL thereafter | Human data show no prostate benefit, so the marker detects change rather than confirms effect |
| Estradiol (women in transition) | No established target for this purpose; interpret against menstrual status rather than a cut-off | Places the individual on the estrogen gradient that determines whether a plant estrogen activates or competes |
Cadence: Repeat enterolactone and hs-CRP at 8 weeks, repeat the full panel at 6 months, then every 6–12 months while use continues.